Dolutegravir for pregnant women living with HIV
Dolutegravir is an integrase inhibitor that works by inhibiting the insertion of HIV DNA into host cells, thereby preventing ongoing viral replication. It is considered an important antiretroviral therapy for many patients living with HIV because it has a favorable adverse effect profile and few dru...
Gespeichert in:
| Veröffentlicht in: | Canadian Medical Association journal (CMAJ) 2020-03, Vol.192 (9), p.E217-E218 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E218 |
|---|---|
| container_issue | 9 |
| container_start_page | E217 |
| container_title | Canadian Medical Association journal (CMAJ) |
| container_volume | 192 |
| creator | Zipursky, Jonathan Loutfy, Mona |
| description | Dolutegravir is an integrase inhibitor that works by inhibiting the insertion of HIV DNA into host cells, thereby preventing ongoing viral replication. It is considered an important antiretroviral therapy for many patients living with HIV because it has a favorable adverse effect profile and few drug-drug interactions, is taken once daily as part of a multidrug regimen, and confers a low risk of developing resistance compared with other antiretrovirals. Here, Zipursky and Loutfy examine whether dolutegravir is safe for pregnant women. |
| doi_str_mv | 10.1503/cmaj.191227 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7055948</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A615690976</galeid><sourcerecordid>A615690976</sourcerecordid><originalsourceid>FETCH-LOGICAL-c640t-6f3d84e410b76f761c5ccf355a94eb98ac41d863ecbb7bb13ff4605cccf29b93</originalsourceid><addsrcrecordid>eNqV0k2L1DAABuAgijuunrxLURBFOpuvJs1FWNaPHVgUdPEa0kzSydAms0k7q__eDLOuU5mL6SGQPn2TkheA5wjOUQXJme7Veo4Ewpg_ADNE67rEBIuHYAZrDEsiKDsBT1JawzwI5o_BCcFZC17PwNmH0I2DaaPauljYEItNNK1XfihuQ2980bmt821x64ZVcbn48RQ8sqpL5tndfAquP328vrgsr75-XlycX5WaUTiUzJJlTQ1FsOHMcoZ0pbUlVaUENY2olaZoWTNidNPwpkHEWspgNtpi0QhyCt7vYzdj05ulNn6IqpOb6HoVf8mgnJy-8W4l27CVHFaVoHUOeHMXEMPNaNIge5e06TrlTRiTxIRDKqqaoUxf_UPXYYw-_91OIU4rzPBf1arOSOdtyPvqXag8Z6hiAgrOsiqPqNZ4kw8ZvLEuL0_8yyNeb9yNPETzIyg_S9M7fTT17eSDbAbzc2jVmJJcfP_2H_bL1L4-sCujumGVdv1xwacpfLeHOoaUorH3N4eg3JVW7kor96XN-sXhZd_bPy0lvwF6NOIy</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2371745262</pqid></control><display><type>article</type><title>Dolutegravir for pregnant women living with HIV</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Zipursky, Jonathan ; Loutfy, Mona</creator><creatorcontrib>Zipursky, Jonathan ; Loutfy, Mona</creatorcontrib><description>Dolutegravir is an integrase inhibitor that works by inhibiting the insertion of HIV DNA into host cells, thereby preventing ongoing viral replication. It is considered an important antiretroviral therapy for many patients living with HIV because it has a favorable adverse effect profile and few drug-drug interactions, is taken once daily as part of a multidrug regimen, and confers a low risk of developing resistance compared with other antiretrovirals. Here, Zipursky and Loutfy examine whether dolutegravir is safe for pregnant women.</description><identifier>ISSN: 0820-3946</identifier><identifier>EISSN: 1488-2329</identifier><identifier>DOI: 10.1503/cmaj.191227</identifier><identifier>PMID: 32122978</identifier><language>eng</language><publisher>Canada: Joule Inc</publisher><subject>Antiretroviral drugs ; Children ; Clinical decision making ; Complications and side effects ; Decision making ; Dolutegravir ; Drug therapy ; Efavirenz ; Highly active antiretroviral therapy ; HIV ; HIV infections ; HIV patients ; Human immunodeficiency virus ; Intelligence gathering ; Neural tube defects ; Newborn infants ; Perinatal infection ; Pregnancy ; Pregnant women ; Prescription writing ; Public health ; Risk factors ; Womens health</subject><ispartof>Canadian Medical Association journal (CMAJ), 2020-03, Vol.192 (9), p.E217-E218</ispartof><rights>COPYRIGHT 2020 Joule Inc.</rights><rights>Copyright Joule Inc Mar 2, 2020</rights><rights>2020 Joule Inc. or its licensors 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c640t-6f3d84e410b76f761c5ccf355a94eb98ac41d863ecbb7bb13ff4605cccf29b93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055948/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055948/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32122978$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zipursky, Jonathan</creatorcontrib><creatorcontrib>Loutfy, Mona</creatorcontrib><title>Dolutegravir for pregnant women living with HIV</title><title>Canadian Medical Association journal (CMAJ)</title><addtitle>CMAJ</addtitle><description>Dolutegravir is an integrase inhibitor that works by inhibiting the insertion of HIV DNA into host cells, thereby preventing ongoing viral replication. It is considered an important antiretroviral therapy for many patients living with HIV because it has a favorable adverse effect profile and few drug-drug interactions, is taken once daily as part of a multidrug regimen, and confers a low risk of developing resistance compared with other antiretrovirals. Here, Zipursky and Loutfy examine whether dolutegravir is safe for pregnant women.</description><subject>Antiretroviral drugs</subject><subject>Children</subject><subject>Clinical decision making</subject><subject>Complications and side effects</subject><subject>Decision making</subject><subject>Dolutegravir</subject><subject>Drug therapy</subject><subject>Efavirenz</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV infections</subject><subject>HIV patients</subject><subject>Human immunodeficiency virus</subject><subject>Intelligence gathering</subject><subject>Neural tube defects</subject><subject>Newborn infants</subject><subject>Perinatal infection</subject><subject>Pregnancy</subject><subject>Pregnant women</subject><subject>Prescription writing</subject><subject>Public health</subject><subject>Risk factors</subject><subject>Womens health</subject><issn>0820-3946</issn><issn>1488-2329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqV0k2L1DAABuAgijuunrxLURBFOpuvJs1FWNaPHVgUdPEa0kzSydAms0k7q__eDLOuU5mL6SGQPn2TkheA5wjOUQXJme7Veo4Ewpg_ADNE67rEBIuHYAZrDEsiKDsBT1JawzwI5o_BCcFZC17PwNmH0I2DaaPauljYEItNNK1XfihuQ2980bmt821x64ZVcbn48RQ8sqpL5tndfAquP328vrgsr75-XlycX5WaUTiUzJJlTQ1FsOHMcoZ0pbUlVaUENY2olaZoWTNidNPwpkHEWspgNtpi0QhyCt7vYzdj05ulNn6IqpOb6HoVf8mgnJy-8W4l27CVHFaVoHUOeHMXEMPNaNIge5e06TrlTRiTxIRDKqqaoUxf_UPXYYw-_91OIU4rzPBf1arOSOdtyPvqXag8Z6hiAgrOsiqPqNZ4kw8ZvLEuL0_8yyNeb9yNPETzIyg_S9M7fTT17eSDbAbzc2jVmJJcfP_2H_bL1L4-sCujumGVdv1xwacpfLeHOoaUorH3N4eg3JVW7kor96XN-sXhZd_bPy0lvwF6NOIy</recordid><startdate>20200302</startdate><enddate>20200302</enddate><creator>Zipursky, Jonathan</creator><creator>Loutfy, Mona</creator><general>Joule Inc</general><general>CMA Impact, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200302</creationdate><title>Dolutegravir for pregnant women living with HIV</title><author>Zipursky, Jonathan ; Loutfy, Mona</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c640t-6f3d84e410b76f761c5ccf355a94eb98ac41d863ecbb7bb13ff4605cccf29b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antiretroviral drugs</topic><topic>Children</topic><topic>Clinical decision making</topic><topic>Complications and side effects</topic><topic>Decision making</topic><topic>Dolutegravir</topic><topic>Drug therapy</topic><topic>Efavirenz</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV infections</topic><topic>HIV patients</topic><topic>Human immunodeficiency virus</topic><topic>Intelligence gathering</topic><topic>Neural tube defects</topic><topic>Newborn infants</topic><topic>Perinatal infection</topic><topic>Pregnancy</topic><topic>Pregnant women</topic><topic>Prescription writing</topic><topic>Public health</topic><topic>Risk factors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zipursky, Jonathan</creatorcontrib><creatorcontrib>Loutfy, Mona</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Canadian Medical Association journal (CMAJ)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zipursky, Jonathan</au><au>Loutfy, Mona</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dolutegravir for pregnant women living with HIV</atitle><jtitle>Canadian Medical Association journal (CMAJ)</jtitle><addtitle>CMAJ</addtitle><date>2020-03-02</date><risdate>2020</risdate><volume>192</volume><issue>9</issue><spage>E217</spage><epage>E218</epage><pages>E217-E218</pages><issn>0820-3946</issn><eissn>1488-2329</eissn><abstract>Dolutegravir is an integrase inhibitor that works by inhibiting the insertion of HIV DNA into host cells, thereby preventing ongoing viral replication. It is considered an important antiretroviral therapy for many patients living with HIV because it has a favorable adverse effect profile and few drug-drug interactions, is taken once daily as part of a multidrug regimen, and confers a low risk of developing resistance compared with other antiretrovirals. Here, Zipursky and Loutfy examine whether dolutegravir is safe for pregnant women.</abstract><cop>Canada</cop><pub>Joule Inc</pub><pmid>32122978</pmid><doi>10.1503/cmaj.191227</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0820-3946 |
| ispartof | Canadian Medical Association journal (CMAJ), 2020-03, Vol.192 (9), p.E217-E218 |
| issn | 0820-3946 1488-2329 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7055948 |
| source | DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Antiretroviral drugs Children Clinical decision making Complications and side effects Decision making Dolutegravir Drug therapy Efavirenz Highly active antiretroviral therapy HIV HIV infections HIV patients Human immunodeficiency virus Intelligence gathering Neural tube defects Newborn infants Perinatal infection Pregnancy Pregnant women Prescription writing Public health Risk factors Womens health |
| title | Dolutegravir for pregnant women living with HIV |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T11%3A22%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dolutegravir%20for%20pregnant%20women%20living%20with%20HIV&rft.jtitle=Canadian%20Medical%20Association%20journal%20(CMAJ)&rft.au=Zipursky,%20Jonathan&rft.date=2020-03-02&rft.volume=192&rft.issue=9&rft.spage=E217&rft.epage=E218&rft.pages=E217-E218&rft.issn=0820-3946&rft.eissn=1488-2329&rft_id=info:doi/10.1503/cmaj.191227&rft_dat=%3Cgale_pubme%3EA615690976%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2371745262&rft_id=info:pmid/32122978&rft_galeid=A615690976&rfr_iscdi=true |